Prescription drug · ANDA
Pomalidomide NDC 31722-773
Pomalidomide 4 mg/1 · Capsule · Oral · Camber Pharmaceuticals, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 31722-773-01 | 31722077301 | 100 CAPSULE in 1 BOTTLE (31722-773-01)Marketed from Feb 28, 2026 | |
| 31722-773-21 | 31722077321 | 21 CAPSULE in 1 BOTTLE (31722-773-21)Marketed from Feb 28, 2026 | |
| 31722-773-32 | 31722077332 | 6 BLISTER PACK in 1 CARTON (31722-773-32) / 10 CAPSULE in 1 BLISTER PACKMarketed from Feb 28, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Pomalidomide
- Generic name (nonproprietary)
- pomalidomide
- Active ingredients
- Pomalidomide — 4 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Camber Pharmaceuticals, Inc.
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 210236
- Marketing start
- Listing expires
- Identifiers
- Product ID 31722-773_4c3e8f7f-ef41-3672-e063-6294a90ac5d6SPL ID 4c3e8f7f-ef41-3672-e063-6294a90ac5d6SPL set ID 52676691-e171-467c-ae55-b5dcc14062a4RxCUI 1369718, 1369726, 1369730, 1369734UNII D2UX06XLB5UPC 0331722770217, 0331722772211, 0331722773218, 0331722771214
- Pharmacologic class
- Thalidomide Analog
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N431722077301followed by a unit qualifier and the quantityPackage 31722-0773-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
Pomalidomide is a thalidomide analogue indicated for the treatment of adult patients: • in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). 1.1 Multiple Myeloma Pomalidomide capsules, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 210236
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Pomalidomide | Pomalidomide 3 mg/1 | CapsuleOral | Camber Pharmaceuticals, Inc. | 31722-772 |
| Pomalidomide | Pomalidomide 2 mg/1 | CapsuleOral | Camber Pharmaceuticals, Inc. | 31722-771 |
| Pomalidomide | Pomalidomide 1 mg/1 | CapsuleOral | Camber Pharmaceuticals, Inc. | 31722-770 |